publication venue for
- Correction: COVID-19 Infections and Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers. 2020
- Dynamics of Immune Reconstitution and Impact on Outcomes across CAR-T Cell Products in Large B-cell Lymphoma.. 6. 2025
- Molecular evolution of classic Hodgkin lymphoma revealed through whole genome sequencing of Hodgkin and Reed Sternberg cells. 2023
- In vivo modeling of CLL transformation to Richter's syndrome reveals convergent evolutionary paths and therapeutic vulnerabilities. 2022
- The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.. 3. 2022
- PU.1-Dependent Enhancer Inhibition Separates Tet2-Deficient Hematopoiesis from Malignant Transformation.. 3. 2022
- Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival.. 3. 2021
- Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy.. 2. 2021
- ZBTB33 is mutated in clonal hematopoiesis and myelodysplastic syndromes and impacts RNA splicing.. 2. 2021
- Towards artificial intelligence-driven pathology assessment for hematological malignancies.. 2. 2021
- An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities.. 2. 2021
- COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers.. 1. 2020
- Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies. 2021
- Non-oncogene Addiction to SIRT5 in Acute Myeloid Leukemia. 2021
- Toward More Complete Prognostication for Patients with Clonal Hematopoiesis. 2021
- Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies.. 4. 2023
- Tee-ing up a New Follicular Lymphoma Classification System.. 3. 2022
- Splicing-Mediated Antigen Escape from Immunotherapy for B-cell Malignancies.. 3. 2022
- Advancing CAR T-cell Therapies with Artificial Intelligence: Opportunities and Challenges. 2025
- Addressing Health Disparities in Hematologic Malignancies: from Genes to Outreach. 2025